Background illustration for clinical trials search

Glomerulonephritis Clinical Trials

Browse 76 glomerulonephritis clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Research Accelerated by You Lupus Registry

for
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN),
Location: Washington D.C. DC
Sponsor: Lupus Foundation of America

Sex: All

Age: 0+

Code: NCT06927219

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

for
SLE (Systemic Lupus), Lupus Erythematosus, Systemic,
Location: Boston MA, Chapel Hill NC, Chicago IL, New Orleans LA,
Sponsor: CRISPR Therapeutics

Sex: All

Age: 18 - 70

Code: NCT06925542

Phase 1, Recruiting

A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)

for
Nephrotic Syndrome in Children, Minimal Change Disease,
Location: New Hyde Park NY, Philadelphia PA
Sponsor: Northwell Health

Sex: All

Age: 3 - 17

Code: NCT05583942

Recruiting

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

for
Primary Membranous Nephropathy
Location: New York NY, Fairfax VA, Charlottesville VA,
Sponsor: Cerium Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT05696613

Phase 3, Recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

for
Lupus Nephritis
Location: Queens NY, Hackensack NJ, Montreal, Toronto, Atlanta GA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 5 - 17

Code: NCT05039619

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

for
Focal Segmental Glomerulosclerosis
Location: New York NY, Wilmington DE, Richmond VA, Chapel Hill NC,
Sponsor: Kaneka Medical America LLC

Sex: All

Age: 0 - 70+

Code: NCT04065438

Recruiting

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases

for
Focal Segmental Glomerulosclerosis, Minimal Change Disease,
Location: Bethesda MD
Sponsor: National Human Genome Research Institute (NHGRI)

Sex: All

Age: 18 - 70+

Code: NCT06664814

Phase 2, Recruiting

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

for
FSGS
Location: New York NY, Hackensack NJ, Philadelphia PA,
Sponsor: Dimerix Bioscience Pty Ltd

Sex: All

Age: 12 - 70+

Code: NCT05183646

Phase 3, Recruiting

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

for
Lupus Nephritis, Primary Membranous Nephropathy
Location: Worcester MA, New York NY, Summit NJ, Syracuse NY,
Sponsor: Nkarta, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06557265

Phase 1, Phase 2, Recruiting

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

for
Focal Segmental Glomerulosclerosis
Location: New York NY, Philadelphia PA, Wilmington DE,
Sponsor: Kaneka Medical America LLC

Sex: All

Age: 0 - 21

Code: NCT02235857

Recruiting

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

for
Lupus Nephritis
Location: Baltimore MD, Charlotte NC, Columbus OH, Hixson TN
Sponsor: GlaxoSmithKline

Sex: All

Age: 18+

Code: NCT06527872

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

for
Lupus Nephritis
Location: Manhasset NY, New York NY, Philadelphia PA, Hershey PA,
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Sex: All

Age: 18+

Code: NCT05201469

Phase 2, Recruiting

Study of WAL0921 in Patients With Glomerular Kidney Diseases

for
Diabetic Nephropathies,
Location: Tamarac FL, Atlanta GA, Hinsdale IL, Houston TX,
Sponsor: Walden Biosciences

Sex: All

Age: 18 - 70+

Code: NCT06466135

Phase 2, Recruiting

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

for
Autoimmune Disorders, Systemic Sclerosis,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06434363

Phase 1, Phase 2, Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

for
IC-MPGN
Location: Boston MA, New York NY, Montreal, Philadelphia PA,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 12 - 60

Code: NCT05755386

Phase 3, Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

for
Focal Segmental Glomerulosclerosis, Minimal Change Disease,
Location: New Hyde Park NY, Neptune City NJ, Hackensack NJ,
Sponsor: Travere Therapeutics, Inc.

Sex: All

Age: 1 - 17

Code: NCT05003986

Phase 2, Recruiting

taVNS for FRNS in Children

for
Nephrotic Syndrome in Children, Minimal Change Disease,
Location: New Hyde Park NY, Philadelphia PA
Sponsor: Northwell Health

Sex: All

Age: 3 - 17

Code: NCT05588063

Recruiting

AMPK-activation by Metformin in FSGS: AMP-FSGS

for
Focal Segmental Glomerulosclerosis
Location: New Haven CT, New York NY
Sponsor: Yale University

Sex: All

Age: 18 - 70+

Code: NCT06090227

Phase 1, Phase 2, Recruiting

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

for
SLE, Systemic Lupus Erythematosus (SLE), CAR T Cell, CART19,
Location: Philadelphia PA
Sponsor: Children's Hospital of Philadelphia

Sex: All

Age: 10 - 29

Code: NCT06839976

Phase 1, Phase 2, Recruiting

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

for
Primary IgA Nephropathy
Location: New York NY
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT04557462

Phase 3, Recruiting

Glomerulonephritis is inflammation of the glomeruli, the tiny filters inside the kidneys, and it can quietly cause protein and blood in the urine for years before kidney function declines. It includes several different diseases, such as IgA nephropathy, the most common worldwide, and FSGS, which often affects younger adults. For a long time treatment was limited to blood pressure medicines and broad immune suppression. Recent years brought the first targeted treatments for some forms, and many more are now being tested to protect kidney function before damage becomes permanent.